Navigation Links
What is the role of focal therapy in low-risk prostate cancer?
Date:5/18/2010

May 2010 -- In the July issue of European Urology, the scientific journal of the European Association of Urology (EAU), S. Eggener et al. discussed in a recent study the significance and impact of focal therapy for low-risk cancer patients.

Since the introduction of prostate cancer screening based on prostate-specific antigen (PSA), over-treatment has increased. A significant proportion of patients diagnosed with prostate cancer have well differentiated, low-volume tumours at minimal risk of impacting their quality of life or longevity. The selection of a treatment strategy, among the multitude of options, has enormous implications for individuals and health care systems.

A conceptually appealing option to patients uncomfortable with observational strategies yet highly concerned about the risks of whole-gland treatment is to bridge elements of active surveillance with whole-gland therapy. This hybrid approach, termed focal therapy, aims to eradicate known cancer foci with the highest likelihood of progressing or metastasizing while attempting to diminish collateral damage to the vital structures essential for maintaining normal urinary and sexual function.

Limitations of focal therapy include the inability to stage or grade the cancer(s) accurately, suboptimal imaging capabilities, uncertainty regarding the natural history of untreated cancer foci, challenges with post-treatment monitoring, and the lack of quality-of-life data compared with alternative treatment strategies.

The aim of the present study was to review the rationale, patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for the focal therapy of localized prostate cancer.

A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was performed from 1995 to 2009 using medical subject headings ''focal therapy'' or ''ablative'' and ''prostate cancer'.' Additional articles were extracted based on recommendations from an expert panel of authors.

One of the conclusions of the study is that focal therapy for prostate cancer is a promising and emerging treatment strategy for men with a low risk of cancer progression or metastasis. Evaluation in formal prospective clinical trials is essential before this new strategy is accepted in clinical practice.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. UV LED therapy shows promising results in preventing focal seizures
2. Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer
3. Combination therapy targets stubborn leukemia stem cells
4. Study demonstrates art therapys effectiveness in pediatric asthma
5. Physical Therapy Online Continuing Education Courses Undergo an Inevitable Evolution
6. Complimentary Injury Screenings Available at All AthletiCo Physical and Occupational Therapy Centers
7. Phase II study of an oral therapy for Gaucher disease yields positive results
8. Magnet Therapy May Ease Hard-to-Treat Depression
9. FDA Reviews Side Effects From Prostate Cancer Therapy
10. Finding cancer cold spots can help minimize radiotherapy side-effects
11. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: